Strive, Inc., a NASDAQ-listed asset manager, purchased 469 Bitcoin between September 8-11, 2026, bringing its total Bitcoin holdings to 25,000 BTC. The $36.6 million acquisition was fully funded through preferred stock, avoiding dilution of common shareholders. This milestone places Strive among the top publicly traded corporate Bitcoin holders globally. The company’s preferred stock structure, with over $1 billion in notional value, means Bitcoin price drops could impact treasury value without reducing preferred stock obligations, a key factor for investors to watch.
Strive, Inc.'s Bitcoin holdings reached 25,000 BTC after acquiring an additional 469 BTC. For readers following the cryptocurrency market, here is Pluang's market snapshot as of Sep 14, 2026 18:51 WIB: of 50 major cryptocurrencies priced on Pluang, 33 rose and 15 fell. Notable movers include FIL (Filecoin) up 23.84% at Rp17.676 with a typical hold time of 99 days and a 66% sell order activity, BAL (Balancer) up 11.14% at Rp16.297 with a typical hold time of 85 days, and CAKE (PancakeSwap) up 8.82% at Rp41.097 with a typical hold time of 75 days and 69% buy order activity.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
